New
navigation
for
cancer treatment
News
2025.02.07
Takeshi Iwaya, M.D., Ph.D. from Iwate Medical University gave a talk at Symposium 2 in the 9th Liquid Biopsy Research Meeting (Tokyo).
2025.02.07
Hayato Hiraki Ph.D. from Iwate Medical University gave a talk at the Sponsored Seminar by Quantdetect, Inc. in the 9th Liquid Biopsy Research Meeting (Tokyo).
2025.01.15
Nishizuka gave a talk at Chiba Cancer Center Research Institute Research Conference (Chiba).
New technology provides individualized information for cancer treatment: OTS-Probes and OTS-Assay
A large number of cancer-related gene mutations has been reported, but these mutations do not occur randomly, instead, some sets of mutations have been found many times.
Quantdetect has designed and developed technologies to identify and quantify such recurrent mutations among cancer patients. These technologies, called OTS-Probes and OTS-Assay, have made it possible to track the amount of tumor in the body just by drawing blood.
OTS is an abbreviation for Off-The-Shelf, referring to technologies that prompt your cancer treatment. The OTS-Probes are our originally developed reagents for digital PCR, one of the most sensitive technologies for detecting cancer-related gene mutations. The OTS-Assay includes all steps necessary to quantify gene mutations using the OTS-Probes.
Quantdetect has many pre-made, ready-to-use digital PCR probes as our library. With OTS-Probes, an individualized probe for monitoring a patient’s tumor amount during the OTS-Assay is likely to be immediately available.
Features
OTS-Assay first screens gene mutations from resected tissue, then measure the amount of the same gene mutation in the blood, namely circulating tumor DNA (ctDNA). Previous research has shown the following features:
Early relapse prediction
Elevated ctDNA indicates relapse earlier than currently used methods.
Treatment efficacy evaluation
The dynamics of ctDNA indicate treatment efficacy more objectively than currently used methods.
No relapse corroboration
Very low levels of ctDNA indicates no current relapse and a high likelihood of no relapse for some time.
Large digital PCR probe library
This library holds many individually designed DNA detection reagents.
For all cancer types
In principle, all cancer has some gene mutations. OTS-Assay is based on gene mutations. Therefore, OTS-Assay can be used for many cancer types.
Read in
manga about
technologies
Read in
manga about
technologies
Research & Practice
For cancer research institutions, pharmaceuticals,
and related companies
Quantdetect accepts blood or DNA samples for OTS-Assay on a Research-Use-Only basis. The assay examines whether the ctDNA from the samples reflects dynamics of the tumor amount in the body of a cancer patient who has received any type of cancer treatment. Please contact us if you have blood samples and relevant treatment information.
For those considering
to undergo the OTS-Assay
Quantdetect currently provides OTS-Assay on Research-Use-Only basis. Please contact one of the following institutions for the OTS-Assay.
